The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
October 25th 2024
New research indicates semaglutide reduced albuminuria and body weight in CKD patients without diabetes, highlighting its potential renal benefits.
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
PCI: New Imaging Detects Heart Attack Patients Who Don't Need It
About a quarter of patients who survived heart attacks due to blocked arteries could be treated with drugs, not invasive procedures. The trick is determining whether the blockage is cause by plaque erosion, not plaque rupture. With optical coherence tomography a team in Boston did just that.
Anselm K. Gitt, MD: DYSIS and Increased Persistent Lipid Abnormalities
At the European Society of Cardiology Congress 2016 (ESC) in Rome, Italy, Anselm Gitt, MD discussed the DYSIS program, which was designed to get an idea to see how patients were treated for secondary prevention, focusing on dyslipidemia patients.
Study: Drug-Eluting Stents No Better than Bare Metal
Drug-eluting stents are falling far short of their promises of fewer complications, improved mortality and quality of life, a study found. In the largest study ever done comparing newer drug-eluting stents to bare metal devices, Norwegian researchers found the drug stents did not show a difference in these outcomes.
Michael Lincoff, MD: Lipid Levels & Cardiovascular Outcomes With CETP Inhibition
At the European Society of Cardiology Congress 2016 (ESC) in Rome, Italy, Michael Lincoff, MD, Cleveland Clinic explained results from ACCELERATE trial involving patients with high risk vascular disease who received evacetrapib on top of standard care.
G. Richard Olds: Working with Foreign Governments to Improve Conditions Locally
As one of the leading educational institutions on the island of Grenada, St. George's University plays a unique role not only in helping the students that come to the school to learn but also those who have already called the island home.
G. Richard Olds: New and International Medical Schools Play Key Role in Global Health
Whether medical students learn their craft at the most established institutions or newer schools around the world their ultimate goal is the same, to help the patient in front of them when they enter practice.
Sigrun Halvorsen, MD: Comparing Bleeding Rates in Non-valvular AF Patients Prescribed Anticoagulants
At the European Society of Cardiology Congress 2016 (ESC), Sigrun Halvorsen, MD, Oslo University discussed the results of her study which analyzed the bleeding rates among NVAF patients who were prescribed anticoagulants.
Christopher Granger, MD: Optimizing Stroke Prevention for Atrial Fibrillation
Christopher Granger, MD, professor of medicine, director of the Critical Care Unit at the Duke University Medical Center discussed that the European Society of Cardiology (ESC) has grown to be one of the best forums to discuss best practices of cardiovascular care.
Douglas Mann, MD: Challenging The Prevailing Dogma
Experts at the European Society of Cardiology Congress 2016 (ESC) expressed varied opinions on the DANISH trial. Researchers presented that implantable cardioverter-defibrillators (ICDs) do not work for all heart patients.
Patients See Remote Monitoring of Cardioverters as Beneficial
Not all the news on remote monitoring of cardiac devices was bad at the ESC Congress 2016. Though a UK study had negative findings,Italian researchers said their use reduced office and ED visits and saved patients time and money.
Sonal Bhatia from Pfizer: Consistency in Data For The Last 5 Years
Sonal Bhatia, MD, Vice President, Global Eliquis Medical Lead, Pfizer, highlighted the significance of the consistency in data over the last five years, in relation to the five-year-anniversary of her team's Aristotle study at the European Society of Cardiology 2016 (ESC).